Navigation Links
Skyline Diagnostics and Clavis Pharma to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug elacytarabine
Date:9/6/2011

ROTTERDAM, The Netherlands, September 6, 2011 /PRNewswire/ --

The Dutch biotech company Skyline Diagnostics B.V. (Skyline) and the Norwegian drug development company Clavis Pharma ASA (Clavis) disclosed signing a research agreement. Under this agreement, Skyline will investigate gene expression biomarkers for selection of individual Acute Myeloid Leukemia (AML) patients that may benefit from a new AML drug in development at Clavis. This drug, elacytarabine, is a novel elaidic acid derivative of cytarabine and currently undergoing the CLAVELA phase III study for treatment of patients with relapsed/refractory AML.

"For Clavis and for elacytarabine this is an important collaboration. Skyline Diagnostics's expertise will be instrumental in searching for gene expression patterns that can be utilized in the further biomarker program of elacytarabine," said Athos Gianella-Borradori, CMO of Clavis Pharma, "this genomic approach adds to our currently ongoing patient selection based on  protein markers and will deepen our insights into the potential for precise and highly effective personalized medicines. It is our goal and vision that this collaboration with the experts of Skyline will bring better therapies to the many patients suffering from difficult-to-treat leukemia."

"After the successful launch of the AMLprofiler in Europe, we are pleased to further strengthen our companion diagnostics activities," said Henk Viëtor, CEO of Skyline.

"Pharma companies are recognizing the value of companion diagnostics in positioning their drugs. By applying our bioinformatics engine, product development and regulatory experience, we can add substantial value to the process of drug development. We look forward working together with Clavis Pharma on this exciting personalized medicine opportunity."

About Skyline Diagnostics B.V.

Skyline Diagnostics develops and markets array-based diagnostic tests for personalized medicine. Skyline's product the AMLprofiler simplifies AML diagnostics by replacing 7 separate assays by a single microarray-based test. The company has built strong collaborations with leading scientists and pharmaceutical companies and has several strategic alliances with industrial partners for distribution and manufacturing.

About Clavis Pharma ASA

Clavis Pharma ASA is a late clinical stage oncology discovery and drug development company with a portfolio of novel anti-cancer drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough products may offer improved efficacy and reduced side effects.

http://www.skyline-diagnostics.com

http://www.clavispharma.com


'/>"/>
SOURCE Skyline Diagnostics B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SI-BONE, Inc. Closes $11.0 Million Financing Led by Skyline Ventures
2. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
6. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
10. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
11. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs ... the Lincoln, Neb. area this year. , The first new location will open ... location will open at 84th and Northern Lights Drive this fall. And the third ...
(Date:4/27/2017)... ... ... Are you investing in the safety of your friends and family? Each year, ... most of us assume this type of accident will never happen to us, the ... the time to learn how to respond effectively or prevent these accidents from occurring ...
(Date:4/26/2017)... ... 26, 2017 , ... Jump Technologies, Inc., an innovative software ... completed a round of funding to accelerate its growth strategies. The $3.5 million ... is a growth equity firm focused on investments in healthcare and technology companies. ...
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology – Tooth ... to overall dental health, including complications with speech, eating, and overcompensation of mouth due ... replace lost teeth. As the number of tooth replacements increase, it is imperative to ...
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs ... of e-prescribing as measured in Part D Medicare data. The dataset, called PaPR ... either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data set ...
Breaking Medicine News(10 mins):